BRPI0709759A2 - compostos restrito como antagonista de receptor de cgrp,composição que compreende referido composto e uso do mesmo - Google Patents

compostos restrito como antagonista de receptor de cgrp,composição que compreende referido composto e uso do mesmo Download PDF

Info

Publication number
BRPI0709759A2
BRPI0709759A2 BRPI0709759-0A BRPI0709759A BRPI0709759A2 BR PI0709759 A2 BRPI0709759 A2 BR PI0709759A2 BR PI0709759 A BRPI0709759 A BR PI0709759A BR PI0709759 A2 BRPI0709759 A2 BR PI0709759A2
Authority
BR
Brazil
Prior art keywords
oxo
formula
mixture
mmol
chloro
Prior art date
Application number
BRPI0709759-0A
Other languages
English (en)
Portuguese (pt)
Inventor
V. Chaturvedula Prasad
E. Mercer Stephen
Fang Haiquan
Han Xiaojun
Luo Guanglin
M. Dubowchik Gene
S. Poindexter Graham
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of BRPI0709759A2 publication Critical patent/BRPI0709759A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0709759-0A 2006-05-03 2007-05-02 compostos restrito como antagonista de receptor de cgrp,composição que compreende referido composto e uso do mesmo BRPI0709759A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US79740006P 2006-05-03 2006-05-03
US60/797,400 2006-05-03
US11/742,626 2007-05-01
US11/742,626 US7470680B2 (en) 2006-05-03 2007-05-01 Constrained compounds as CGRP-receptor antagonists
PCT/US2007/067998 WO2007131020A2 (en) 2006-05-03 2007-05-02 Constrained compounds as cgrp-receptor antagonists

Publications (1)

Publication Number Publication Date
BRPI0709759A2 true BRPI0709759A2 (pt) 2011-10-25

Family

ID=38544174

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0709759-0A BRPI0709759A2 (pt) 2006-05-03 2007-05-02 compostos restrito como antagonista de receptor de cgrp,composição que compreende referido composto e uso do mesmo

Country Status (14)

Country Link
US (1) US7470680B2 (https=)
EP (1) EP2013214B1 (https=)
JP (1) JP2009535429A (https=)
KR (1) KR20090018930A (https=)
AR (1) AR060845A1 (https=)
AU (1) AU2007248038A1 (https=)
BR (1) BRPI0709759A2 (https=)
CA (1) CA2651033A1 (https=)
IL (1) IL195027A0 (https=)
MX (1) MX2008013760A (https=)
NO (1) NO20084564L (https=)
PE (1) PE20080232A1 (https=)
TW (1) TW200813063A (https=)
WO (1) WO2007131020A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7384931B2 (en) * 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
EP2120564A4 (en) * 2006-12-20 2011-05-04 Merck Sharp & Dohme BENZAZEPINE COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS
JP2011512410A (ja) * 2008-02-19 2011-04-21 メルク・シャープ・エンド・ドーム・コーポレイション イミダゾベンゾアゼピンcgrp受容体アンタゴニスト
US8685969B2 (en) 2010-06-16 2014-04-01 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
WO2024220626A1 (en) * 2023-04-20 2024-10-24 Azkarra Therapeutics, Inc. Small molecule modulators of ogg1

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7205293B2 (en) 2003-03-14 2007-04-17 Merck & Co., Inc. Benodiazepine spirohydantoin CGRP receptor antagonists
CA2518830A1 (en) 2003-03-14 2004-09-30 Merck & Co., Inc. Carboxamide spirohydantoin cgrp receptor antagonists
JP4705908B2 (ja) * 2003-04-15 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Cgrp受容体拮抗薬
JO2355B1 (en) * 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
WO2005000807A2 (en) 2003-06-26 2005-01-06 Merck & Co., Inc. Benzodiazepine cgrp receptor antagonists
CA2529196A1 (en) 2003-06-26 2005-02-17 Merck & Co., Inc. Benzodiazepine cgrp receptor antagonists
JP4705922B2 (ja) 2004-01-29 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Cgrp受容体拮抗薬
US7390798B2 (en) 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
CA2582593A1 (en) 2004-10-07 2006-04-20 Merck & Co., Inc. Cgrp receptor antagonists
BRPI0517418A (pt) 2004-10-13 2008-10-07 Merck & Co Inc composto, composição farmacêutica, e, métodos para antagonismo de atividade do receptor de cgrp em um mamìfero, para tratar, controlar, melhorar ou reduzir o risco de dor de cabeça, enxaqueca ou cefalgia, e de tratamento ou prevenção de dores de cabeça de enxaqueca, cefalgias, e dores de cabeça
AU2005295855B2 (en) 2004-10-14 2011-08-18 Merck Sharp & Dohme Corp. CGRP receptor antagonists
AU2005299852B2 (en) 2004-10-22 2011-08-04 Merck Sharp & Dohme Corp. CGRP receptor antagonists
US7384931B2 (en) * 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384930B2 (en) * 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
CA2594940A1 (en) 2005-01-18 2006-07-27 Merck & Co., Inc. Cgrp receptor antagonists
CN101208303A (zh) 2005-03-14 2008-06-25 默克公司 Cgrp受体拮抗剂
WO2007016087A2 (en) 2005-07-29 2007-02-08 Merck & Co., Inc. Heterocyclic benzodiazepine cgrp receptor antagonists
EP2120564A4 (en) 2006-12-20 2011-05-04 Merck Sharp & Dohme BENZAZEPINE COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS

Also Published As

Publication number Publication date
KR20090018930A (ko) 2009-02-24
WO2007131020A2 (en) 2007-11-15
US7470680B2 (en) 2008-12-30
CA2651033A1 (en) 2007-11-15
EP2013214A2 (en) 2009-01-14
JP2009535429A (ja) 2009-10-01
AR060845A1 (es) 2008-07-16
TW200813063A (en) 2008-03-16
MX2008013760A (es) 2008-11-14
AU2007248038A1 (en) 2007-11-15
WO2007131020A3 (en) 2008-01-17
US20070259851A1 (en) 2007-11-08
PE20080232A1 (es) 2008-04-11
IL195027A0 (en) 2009-08-03
NO20084564L (no) 2008-12-02
EP2013214B1 (en) 2015-06-24

Similar Documents

Publication Publication Date Title
US7544680B2 (en) Constrained compounds as CGRP-receptor antagonists
JP5116687B2 (ja) がんおよび他の過剰増殖性疾患の処置のためのピロロ[2,1−f][1,2,4]トリアジン−4−イルアミンIGF−1Rキナーゼ阻害剤
MX2014008913A (es) Nuevos derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
WO2007130860A2 (en) Constrained compounds as cgrp-receptor antagonists
CN112584898B (zh) P2x3受体拮抗剂
BRPI0709759A2 (pt) compostos restrito como antagonista de receptor de cgrp,composição que compreende referido composto e uso do mesmo
PT2356123E (pt) Espiro-5,6-di-hidro-4h-2,3,5,10b-tetra-azabenzo[ e]azulenos
ES2368456T3 (es) Compuestos restringidos como antagonistas del receptor de cgrp.
CN101495480B (zh) 作为降钙素基因相关肽受体拮抗剂的受限化合物
AU2006245517A1 (en) Quinoline derivatives as neurokinin receptor antagonists
CN121949345A (zh) 杂芳基大环化合物及其制备方法和应用
BR112021000103B1 (pt) Composto de fórmula i, uso de um composto e composição farmacêutica compreendendo um composto

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A E 5A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012.